REVENUE RECOGNITION AND RELATED ALLOWANCES - Disaggregation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
Disaggregation of Revenue [Line Items]
Total net revenues	$ 211,371	$ 138,040	$ 408,493	$ 275,470
Rare Disease and Brands total net revenues
Disaggregation of Revenue [Line Items]
Total net revenues	117,158	59,220	211,240	121,836
Rare Disease total net revenues
Disaggregation of Revenue [Line Items]
Total net revenues	103,963	49,193	172,922	86,130
Cortrophin Gel
Disaggregation of Revenue [Line Items]
Total net revenues	81,647	49,193	134,497	86,130
ILUVIEN and YUTIQ
Disaggregation of Revenue [Line Items]
Total net revenues	22,316	0	38,425	0
Brands
Disaggregation of Revenue [Line Items]
Total net revenues	13,195	10,027	38,318	35,706
Generics and Other total net revenues
Disaggregation of Revenue [Line Items]
Total net revenues	94,213	78,820	197,253	153,634
Generic pharmaceutical products
Disaggregation of Revenue [Line Items]
Total net revenues	90,297	73,964	188,975	144,181
Royalties and other pharmaceutical services
Disaggregation of Revenue [Line Items]
Total net revenues	$ 3,916	$ 4,856	$ 8,278	$ 9,453